tetano
Editor, Senior Moderator
J Med Case Rep
. 2022 Nov 16;16(1):437.
doi: 10.1186/s13256-022-03592-4.
Miller-Fisher syndrome after first dose of Oxford/AstraZeneca coronavirus disease 2019 vaccine: a case report
Fernanda Junqueira Cesar Pirola[SUP] 1 [/SUP], Bruno Antônio Müzel Santos[SUP] 2 [/SUP], Gabriela Feres Sapienza[SUP] 2 [/SUP], Lucas Yuri Cetrangolo[SUP] 3 [/SUP], Caio Henrique Wthen Gambacorta Geranutti[SUP] 3 [/SUP], Paulo Henrique Pires de Aguiar[SUP] 4 [/SUP]
Affiliations
Abstract
Introduction: Miller-Fisher Syndrome (MFS) is a variant of Guillain-Barré syndrome (GBS), an acute immune-mediated neuropathy, which manifests as a rapidly evolving areflex motor paralysis. This syndrome presents as a classic triad: ophthalmoplegia, areflexia, and ataxia. MFS is usually benign and self-limited.
Case report: A Caucasian patient was admitted to our hospital with the flu, loss of bilateral strength in the lower limbs and upper limbs and sudden-onset ataxia 7 days after receiving a first dose of the Oxford/AstraZeneca COVID-19 vaccine. On neurological examination, the patient had Glasgow Coma Scale score of 15, with absence of meningeal signs; negative Babinski sign; grade 2 strength in the lower limbs and grade 4 strength in the upper limbs; axial and appendicular cerebellar ataxia; and peripheral facial diparesis predominantly on the right, without conjugate gaze deviation. Cerebrospinal fluid (CSF) was collected on admission, and analysis revealed albuminocytological dissociation with CSF protein of 148.9 mg/dL; leukocytes, 1; chlorine, 122; glucose, 65 mg/mL; red cells, 2; and non-reactive venereal disease research laboratory test result. The COVID-19 IgG/IgM rapid immunological test was negative. Electroneuromyography revealed a recent moderate-grade and primarily sensory and motor demyelinating polyneuropathy with associated proximal motor block.
Discussion and conclusion: Miller-Fisher Syndrome may be related to events other than infections prior to neuropathy, as in the case reported here. The patient presented strong correlations with findings for MFS reported in the literature, such as the clinical condition, the results of electroneuromyography, and results of the CSF analysis typical for MFS. When treatment was provided as proposed in the literature, the disease evolved with improvement. Ultimately, the diagnosis of incomplete MFS was made, including acute ataxic neuropathy (without ophthalmoplegia).
Keywords: Areflexia; AstraZeneca vaccine; Ataxia; COVID-19; COVID-19 vaccine; Guillain–Barré syndrome; Miller Fisher syndrome; Ophthalmoplegia; Oxford vaccine.
. 2022 Nov 16;16(1):437.
doi: 10.1186/s13256-022-03592-4.
Miller-Fisher syndrome after first dose of Oxford/AstraZeneca coronavirus disease 2019 vaccine: a case report
Fernanda Junqueira Cesar Pirola[SUP] 1 [/SUP], Bruno Antônio Müzel Santos[SUP] 2 [/SUP], Gabriela Feres Sapienza[SUP] 2 [/SUP], Lucas Yuri Cetrangolo[SUP] 3 [/SUP], Caio Henrique Wthen Gambacorta Geranutti[SUP] 3 [/SUP], Paulo Henrique Pires de Aguiar[SUP] 4 [/SUP]
Affiliations
- PMID: 36384584
- DOI: 10.1186/s13256-022-03592-4
Abstract
Introduction: Miller-Fisher Syndrome (MFS) is a variant of Guillain-Barré syndrome (GBS), an acute immune-mediated neuropathy, which manifests as a rapidly evolving areflex motor paralysis. This syndrome presents as a classic triad: ophthalmoplegia, areflexia, and ataxia. MFS is usually benign and self-limited.
Case report: A Caucasian patient was admitted to our hospital with the flu, loss of bilateral strength in the lower limbs and upper limbs and sudden-onset ataxia 7 days after receiving a first dose of the Oxford/AstraZeneca COVID-19 vaccine. On neurological examination, the patient had Glasgow Coma Scale score of 15, with absence of meningeal signs; negative Babinski sign; grade 2 strength in the lower limbs and grade 4 strength in the upper limbs; axial and appendicular cerebellar ataxia; and peripheral facial diparesis predominantly on the right, without conjugate gaze deviation. Cerebrospinal fluid (CSF) was collected on admission, and analysis revealed albuminocytological dissociation with CSF protein of 148.9 mg/dL; leukocytes, 1; chlorine, 122; glucose, 65 mg/mL; red cells, 2; and non-reactive venereal disease research laboratory test result. The COVID-19 IgG/IgM rapid immunological test was negative. Electroneuromyography revealed a recent moderate-grade and primarily sensory and motor demyelinating polyneuropathy with associated proximal motor block.
Discussion and conclusion: Miller-Fisher Syndrome may be related to events other than infections prior to neuropathy, as in the case reported here. The patient presented strong correlations with findings for MFS reported in the literature, such as the clinical condition, the results of electroneuromyography, and results of the CSF analysis typical for MFS. When treatment was provided as proposed in the literature, the disease evolved with improvement. Ultimately, the diagnosis of incomplete MFS was made, including acute ataxic neuropathy (without ophthalmoplegia).
Keywords: Areflexia; AstraZeneca vaccine; Ataxia; COVID-19; COVID-19 vaccine; Guillain–Barré syndrome; Miller Fisher syndrome; Ophthalmoplegia; Oxford vaccine.